Could one drug be enough? new study challenges combo therapy for IBD

NCT ID NCT07564609

First seen May 07, 2026 · Last updated May 08, 2026 · Updated 1 time

Summary

This study compares two treatments for Crohn's disease and ulcerative colitis: using the drug infliximab alone versus infliximab plus another immune-suppressing drug. The goal is to see if the single drug is just as good at keeping patients in remission without steroids. About 420 adults who have already started infliximab will be followed for at least 3 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Amiens

    Amiens, France

  • CHU Besançon

    Besançon, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, 63000, France

  • CHU Dijon

    Dijon, France

  • CHU Grenoble

    Grenoble, France

  • CHU Lille

    Lille, France

  • CHU Monptellier

    Montpellier, France

  • CHU Nancy

    Nancy, France

  • CHU Nantes

    Nantes, France

  • CHU Nîmes

    Nîmes, France

  • CHU Rouen

    Rouen, France

  • CHU Toulouse

    Toulouse, France

  • Hospice Civil de Lyon

    Lyon, France

  • Hôpital Beaujon AP-HP

    Clichy, France

  • Hôpital Bicêtre AP-HP

    Le Kremlin-Bicêtre, France

  • Hôpital Henri-Mondor AP-HP

    Créteil, France

  • Hôpital Henri-Mondor AP-HP

    Marseille, France

  • Institut des MICI

    Neuilly-sur-Seine, France

Conditions

Explore the condition pages connected to this study.